Literature DB >> 2586565

Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites.

M M Stanley1, S Ochi, K K Lee, B A Nemchausky, H B Greenlee, J I Allen, M J Allen, R A Baum, T R Gadacz, D S Camara.   

Abstract

The optimal management of severe ascites in patients with alcoholic cirrhosis has not been defined. in a 5 1/2-year study, we randomly assigned 299 men with alcoholic cirrhosis, who had persistent or recurrent severe ascites despite a standard medical regimen, to receive either intensive medical treatment or peritoneovenous (LeVeen) shunting. We identified three risk groups: Group 1 had normal or mildly abnormal results on liver-function tests, Group 2 had more severe liver dysfunction or previous complications, and Group 3 had severe prerenal azotemia without kidney disease. For the patients who received the medical treatment and those who received the surgical treatment combined, the median survival times were 1093 days in Group 1, 222 days in Group 2, and 37 days in Group 3 (P less than or equal to 0.01) for all comparisons). For all the groups combined, the median time to the resolution of ascites was 5.4 weeks for medical patients and 3.0 weeks for surgical patients (P less than 0.01). Within each risk group, mortality during the initial hospitalization and median long-term survival were similar among patients receiving either treatment. However, the median time to the recurrence of ascites in Group 1 was 4 months in medical patients, as compared with 18 months in surgical patients (P = 0.01); in Group 2 it was 3 months in medical patients as compared with 12 months in surgical patients (P = 0.04). The median duration of hospitalization was longer in medical patients than in surgical patients (6.1 vs. 2.4 weeks in Group 1 [P less than 0.001] and 5.0 vs. 3.1 weeks in Group 2 [P less than 0.01]). Group 3 was too small to permit a meaningful comparison. During the initial hospitalization, the incidence of infections, gastrointestinal bleeding, and encephalopathy was similar among the medical and surgical patients. We conclude that peritoneovenous shunting alleviated disabling ascites more rapidly than medical management. However, survival was closely related to the severity of the illness at the time of randomization and was not altered by shunting.

Entities:  

Mesh:

Year:  1989        PMID: 2586565     DOI: 10.1056/NEJM198912143212403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  30 in total

Review 1.  Integration of palliative care in end-stage liver disease and liver transplantation.

Authors:  Jamie Potosek; Michael Curry; Mary Buss; Eva Chittenden
Journal:  J Palliat Med       Date:  2014-11       Impact factor: 2.947

2.  TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial.

Authors:  Alexander S Rosemurgy; Emmanuel E Zervos; Whalen C Clark; Donald P Thometz; Thomas J Black; Bruce R Zwiebel; Bruce T Kudryk; L Shane Grundy; Larry C Carey
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

3.  Hepatobiliary quiz-7 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-09

4.  Guidelines on the management of ascites in cirrhosis.

Authors:  K P Moore; G P Aithal
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

5.  A dedicated paracentesis clinic decreases healthcare utilization for serial paracenteses in decompensated cirrhosis.

Authors:  Yao-Wen Cheng; Kumar Sandrasegaran; Katherine Cheng; Angela Shah; Marwan Ghabril; William Berry; Craig Lammert; Naga Chalasani; Eric S Orman
Journal:  Abdom Radiol (NY)       Date:  2018-08

6.  Continuous furosemide infusion in the management of ascites.

Authors:  Nicholas A Rogers; Samir Gupta; Jennifer A Cuthbert
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 7.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

8.  Trans-jugular intrahepatic porto-systemic shunt placement for refractory ascites: a 'real-world' UK health economic evaluation.

Authors:  Matthew J Parker; Neil Guha; Brian Stedman; Nigel Hacking; Mark Wright
Journal:  Frontline Gastroenterol       Date:  2012-03-22

9.  Ascites.

Authors:  Nelson Garcia; Arun J. Sanyal
Journal:  Curr Treat Options Gastroenterol       Date:  2001-12

Review 10.  Surgical management of portal hypertension.

Authors:  J C Collins; I J Sarfeh
Journal:  West J Med       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.